[EN] PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES<br/>[FR] INHIBITEURS DE JAK3 DE TYPE PYRROLOPYRIDAZINE ET LEUR UTILISATION POUR TRAITER LES MALADIES INFLAMMATOIRES ET AUTO-IMMUNES
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2012125886A1
公开(公告)日:2012-09-20
Disclosed are compounds of Formula (I), and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.
[EN] TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS<br/>[FR] INHIBITEURS DE LA BTK COMPRENANT UNE IMIDAZOPYRAZINE D'ALCOOL TERTIAIRE
申请人:MERCK SHARP & DOHME
公开号:WO2016106624A1
公开(公告)日:2016-07-07
Provided are Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, or their use in therapy.
Synthesis of cyclopentane analogs of 1-(2′,3′-dideoxy-β-<i>glycero</i>-pentofuranosyl)pyrimidine nucleosides
作者:Lucjan J. J. Hronowski、Walter A. Szarek
DOI:10.1139/v88-009
日期:1988.1.1
Synthesis of new carbocyclic analogs of 1-(2′,3′-dideoxy-glycero-pentofuranosyl)pyrimidine nucleosides having the uracil (34), 2-thiouracil (33), 2-thiothymine (31), cytosine (44), and 5-methylcytosine (43) bases is described. The nucleoside analogs having the uracil, 2-thiouracil, and 2-thiothymine bases were prepared by coupling cis-3-aminocyclopentanemethanol (8) with 3-ethoxypropenoyl isocyanate
PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
申请人:Wrobleski Stephen T.
公开号:US20140011795A1
公开(公告)日:2014-01-09
Disclosed are compounds of Formula (I), and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.
Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
申请人:Wrobleski Stephen T.
公开号:US08921368B2
公开(公告)日:2014-12-30
Disclosed are compounds of Formula (I), and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.